|Organovo Holdings, Inc.|
6275 Nancy Ridge Drive
United States - Map
Organovo Holdings, Inc., a development-stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development; and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting and nerve grafts for nerve damage repair, as well as functional tissue patches for the repair or replacement of damaged tissues and organs. Organovo Holdings, Inc. has collaboration agreements with United Therapeutics Corporation; Knight Cancer Institute at Oregon Health & Science University; Michael J. Fox Foundation; Hoffman La Roche; and LOreal. The company was founded in 2007 and is headquartered in San Diego, California.
|Mr. Keith Murphy ,
Chairman, Chief Exec. Officer, Pres, Member of Audit Committee and Member of Science & Technology Committee
|Mr. Barry D. Michaels ,
Chief Financial Officer, Principal Accounting Officer and Sec.
|Dr. Sharon Collins Presnell Ph.D.,
Chief Technology Officer and Exec. VP of R&D
|Mr. Michael Renard ,
Exec. VP of Commercial Operations
|Dr. Eric Michael David M.D., J.D., Ph.D.,
Chief Strategy Officer
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|